H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone
Top Cited Papers
- 1 December 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 10 (12) , 1968-1987
Abstract
Glycine 34-to-tryptophan (G34W) substitutions in H3.3 arise in approximately 90% of giant cell tumor of bone (GCT). Here, we show H3.3 G34W is necessary for tumor formation. By profiling the epigenome, transcriptome, and secreted proteome of patient samples and tumor-derived cells CRISPR–Cas9-edited for H3.3 G34W, we show that H3.3K36me3 loss on mutant H3.3 alters the deposition of the repressive H3K27me3 mark from intergenic to genic regions, beyond areas of H3.3 deposition. This promotes redistribution of other chromatin marks and aberrant transcription, altering cell fate in mesenchymal progenitors and hindering differentiation. Single-cell transcriptomics reveals that H3.3 G34W stromal cells recapitulate a neoplastic trajectory from a SPP1+ osteoblast-like progenitor population toward an ACTA2+ myofibroblast-like population, which secretes extracellular matrix ligands predicted to recruit and activate osteoclasts. Our findings suggest that H3.3 G34W leads to GCT by sustaining a transformed state in osteoblast-like progenitors, which promotes neoplastic growth, pathologic recruitment of giant osteoclasts, and bone destruction. Significance: This study shows that H3.3 G34W drives GCT tumorigenesis through aberrant epigenetic remodeling, altering differentiation trajectories in mesenchymal progenitors. H3.3 G34W promotes in neoplastic stromal cells an osteoblast-like progenitor state that enables undue interactions with the tumor microenvironment, driving GCT pathogenesis. These epigenetic changes may be amenable to therapeutic targeting in GCT. See related commentary by Licht, p. 1794. This article is highlighted in the In This Issue feature, p. 1775Keywords
All Related Versions
Funding Information
- Government of Ontario (13513)
- NIH (P01-CA196539)
- NIH (R01CA148699, R01CA159859)
- Canadian Institutes for Health Research (MOP-286756, FDN-154307)
- Canadian Institutes for Health Research (PJT-156086)
- Canadian Cancer Society (705182)
- NSERC (RGPIN-2016-04911)
- CFI Leaders Opportunity Fund (33902)
- Compute Canada Resource Allocation Project (WST-164-AB)
- Canada Cancer Stem Cell Dream Team Research (SU2C-AACR-DT-19-15)
- Government of Ontario (# 80550 6730 RR0001)
- CPRIT (RR170023)
- Terry Fox Research Institute (1087)
This publication has 69 references indexed in Scilit:
- Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomasActa Neuropathologica, 2013
- A short-term in vivo model for giant cell tumor of boneBMC Cancer, 2011
- Histone H3K27ac separates active from poised enhancers and predicts developmental stateProceedings of the National Academy of Sciences, 2010
- Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic RegionsCell, 2010
- Morphological and immunophenotypic features of primary and metastatic giant cell tumour of boneVirchows Archiv, 2009
- Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRtNature Protocols, 2009
- TRPV4-Mediated Calcium Influx Regulates Terminal Differentiation of OsteoclastsCell Metabolism, 2008
- Isolation of Human Prostatic Epithelial Plasma Membranes for Proteomics Using Mirror Image Tissue Banking of Radical Prostatectomy SpecimensClinical Cancer Research, 2006
- Dimethylation of Histone H3 at Lysine 36 Demarcates Regulatory and Nonregulatory Chromatin Genome-WideMolecular and Cellular Biology, 2005
- Partitioning and Plasticity of Repressive Histone Methylation States in Mammalian ChromatinMolecular Cell, 2003